Protection against Delta five times higher with Covaxin booster: Study

Authors say Covaxin is the first in India to report safety and immunogenicity results from a booster clinical trial

Protection against Delta five times higher with Covaxin booster: Study

A student receives a vaccine dose in Chennai on Saturday. PTI

Tribune News Service

New Delhi, January 8

Bharat Biotech on Saturday announced results from the highly anticipated trial studying the immunogenicity and safety of the Covaxin (BBV152) a whole-virion inactivated Covid-19 vaccine as a booster dose and said studies had shown the booster dose offered five times higher protection than the primary two-dose regime of Covaxin.

India will begin the rollout of boosters for health workers and 60-plus people with comorbidities from January 10. The study authors said Covaxin was the first in India to report safety and immunogenicity results from a booster clinical trial — a phase-2 double-blind, randomised controlled trial.

  • Fresh cases 1,41,986
  • Total deaths 4,83,463
  • Avtive cases 4,72,169
  • 285 deaths in 24 hours

The analysis showed six months after a two-dose BBV152 vaccination series cell-mediated immunity and neutralising antibodies to both homologous and heterologous strains (Alpha, Beta, Delta, and Delta plus) persisted above baseline, although the magnitude of the responses had declined.

Furthermore, neutralising antibodies against homologous (same dose) and heterologous (mixed dose) SARS-CoV-2 variants increased 19 to 265 fold after a third vaccination.

Booster BBV152 vaccination is safe and may be necessary to ensure persistent immunity to prevent breakthrough infections, researchers said, adding neutralisation titers against the wild type and Delta variants was five times higher than after a two-dose schedule.

Over 2 crore adolescents get first dose

New Delhi: More than 2 crore children aged 15 to 18 years have received the first dose of Covid-19 within five days of the commencement of Covid inoculation drive for children. India has overall administered 1,50,61,92,903 doses. More than 91 per cent of the adults have now been covered with the first dose and over 66 per cent have been fully inoculated. TNS

Tribune Shorts


Top Stories

Congress will take decision on CM face for Punjab after discussions with party workers: Rahul Gandhi

Congress will soon announce party's CM face in Punjab: Rahul Gandhi

'Both Sidhu and Channi are of the opinion that two cannot le...

Air India handed over to Tata Group

Tata Group takes over Air India

Group company chairman N Chandrasekaran meets PM Modi ahead ...

1984 anti-Sikh riots: HC asks SIT to respond to plea for action against Congress leader Kamal Nath

1984 anti-Sikh riots: HC asks SIT to respond to plea for action against Congress leader Kamal Nath

The case is related to a mob of rioters storming the Gurdwar...

Apex drug regulator grants conditional market approval to Covaxin and Covishield

Regular market approval granted for Covishield, Covaxin for use in adult population

The approval has been granted under the New Drugs and Clinic...

Chinese Army hands over missing Arunachal boy to Indian Army: Minister

Chinese Army hands over missing Arunachal boy to Indian Army: Minister

The 19-year-old Miram Taron of Jido Village in Upper Siang D...

Cities

View All